Skip to main content
Przejdź do strony domowej Komisji Europejskiej (odnośnik otworzy się w nowym oknie)
polski pl
CORDIS - Wyniki badań wspieranych przez UE
CORDIS

Bioorthogonal Prodrug Activation at Nanomolar Levels

Cel

Bioorthogonal click-to-release chemistry enables selective bond cleavage in complex biological environments and has emerged as a powerful concept for controlled prodrug activation, most prominently through trans-cyclooctenes and tetrazines. However, established systems face trade-offs between reaction speed, release efficiency, and stability, limiting their application in therapeutic settings. We have discovered a strained cleavable trans-cyclooctene linker that uniquely combines ultrafast click kinetics with high release efficiency and stability. Compared to current approaches, this TCO exhibits more than 20-fold faster click reactivity, enabling activation under conditions not accessible with existing methods. This advance enables efficient prodrug activation even at nanomolar concentrations, opening new possibilities for targeted therapeutic strategies that remain out of reach. The project will establish proof of concept by developing TCO-caged prodrugs of clinically relevant therapeutics and validating this process using tetrazine triggers, including scaffolds already advanced to clinical trials. Release kinetics, stability in biological media, and biological activity will be systematically evaluated in solution and cellular models. A central concept of the project is click accumulation, where ultrafast kinetics enable local capture and activation of circulating prodrugs. This will be demonstrated in microfluidic models that mimic vascular flow, providing evidence for efficient activation and therapeutic efficacy at low systemic concentrations. Supported by an initial patent filing, this technology represents a versatile platform with strong translational potential. It is expected to create new opportunities for safer and more effective targeted therapeutics, with potential applications in prodrug strategies and related delivery systems.

Dziedzina nauki (EuroSciVoc)

Projekt nie został jeszcze sklasyfikowany według klasyfikacji EuroSciVoc.
Wskaż dziedziny nauki, które twoim zdaniem są najbardziej istotne z punktu widzenia tego projektu i pomóż nam usprawnić naszą usługę klasyfikacji.

Słowa kluczowe

Program(-y)

Temat(-y)

System finansowania

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Wyświetl wszystkie projekty finansowane w ramach tego programu finansowania

Zaproszenie do składania wniosków

(odnośnik otworzy się w nowym oknie) ERC-2026-POC

Wyświetl wszystkie projekty finansowane w ramach tego zaproszenia

Instytucja przyjmująca

TECHNISCHE UNIVERSITAET WIEN
Wkład UE netto
€ 150 000,00
Koszt całkowity
Brak danych

Beneficjenci (1)